Prescriber Adherence to Antihypertensive Prescription Guidelines and the Impact of Patient Socioeconomic Factors: A Cross‐Sectional Study Using Data From the Irish Longitudinal Study on Ageing
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.70025 ↗Kurz gefasst
Leitlinie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Alizeh Akhtar und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University College Cork, Cork, Ireland. Hauptthemen laut MEDLINE: Antihypertensive Agents, Hypertension, Guideline Adherence, Practice Patterns, Physicians'. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Uncontrolled hypertension causes significant morbidity and mortality worldwide. Several prescribing guidelines have been created to address this, however, prescriber adherence to guidelines is influenced by various sociodemographic patient factors. This study aims to determine the effects of these patient factors on prescriber adherence to antihypertensive prescription guidelines.
Methods
A secondary analysis of data from the first wave of The Irish Longitudinal Study on Ageing (TILDA), was conducted. Participants were included if they reported previous hypertension diagnoses. Antihypertensive medication regimes were compared with the prescribing guidance in the 2011 NICE hypertension guidelines. The effects of patient sociodemographic factors on prescriber adherence to guidelines, and the effect of prescriber adherence on blood pressure control (≥ 140/90 mmHg), were determined using binomial logistic regression models.
Results
A total of 2992 participants were included in this analysis; 54.9% female with mean age 65.7 years (±9.23). Male sex and older age, and lower socioeconomic status were associated with increased prescriber guideline adherence. Prescribers were less likely to adhere to guidelines in female patients ≥ 55 years (Relative Risk [RR] 0.75 [0.62, 0.91]), and female patients across all age groups (RR 0.80 [0.67, 0.95]). Better blood pressure control was seen with medication regimes adherent to prescription guidelines (140.38 (±18.98)/83.09 (±11.02) mmHg adherent vs. 141.66 (±19.86)/84.77 (±11.71) mmHg non‐adherent).
Conclusions
This study highlights the effect of patient sex on prescriber adherence to antihypertensive prescription guidelines, emphasizing a larger issue of systemic undertreatment of females observed within healthcare. Further research is needed to determine the reasons for such differences in hypertensive care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, University College Cork, Cork, Ireland.
- School of Medicine, University College Cork, Cork, Ireland.
- Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Cork, Ireland.
ORCID-Profile: Alizeh Akhtar, Edel Burton, Margaret Bermingham, Patricia M Kearney
Zitieren
APA
Akhtar, A., Burton, E., Bermingham, M., & Kearney, P. M. (2024). Prescriber Adherence to Antihypertensive Prescription Guidelines and the Impact of Patient Socioeconomic Factors: A Cross‐Sectional Study Using Data From the Irish Longitudinal Study on Ageing. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70025
Vancouver
Akhtar A, Burton E, Bermingham M, Kearney PM. Prescriber Adherence to Antihypertensive Prescription Guidelines and the Impact of Patient Socioeconomic Factors: A Cross‐Sectional Study Using Data From the Irish Longitudinal Study on Ageing. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70025
BibTeX
@article{Akhtar2024,
author = {Akhtar, Alizeh and Burton, Edel and Bermingham, Margaret and Kearney, Patricia M},
title = {Prescriber Adherence to Antihypertensive Prescription Guidelines and the Impact of Patient Socioeconomic Factors: A Cross‐Sectional Study Using Data From the Irish Longitudinal Study on Ageing},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.70025}
}
EUVIMED